2nd Inner Ear Disorders Therapeutics Summit

Kongressthemen
There are currently no therapeutics on the market for inner ear disorders, so biotech companies have been paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. With the first in-person gene therapy clinical trial commencing in early 2022, the field is booming with excitement, not to mention pharma sparking an interest with increasing investment into these pipelines in the race to successfully reverse hearing damage.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/1053180-3?pid=4832.

Speakers: Carmine Stengone, Chief Executive Officer, Pipeline Therapeutics, David Lucchino Co-Founder, President and Chief Executive Officer, Frequency Therapeutics, and more.

https://go.evvnt.com/1053180-2?pid=4832

Frau Ellie Saunders